This is How Contagious Covid-19 Will Be: Recent Insights on the BA.2.86 Omicron Subvariant

The new variant BA.2.6 Omicron subvariant initially sparked concerns when experts tracking variants observed a few new genetic sequences appearing in worldwide virus databases, exhibiting a significant number of genetic alterations distinct from other prevalent strains. Experiments conducted in Boston, which conform with the experiments in Sweden and China, have indicated that antibodies against BA.2.86 are comparable, and in some cases, even slightly more effective, than those against existing variants. Similar findings were reported at Columbia University, suggesting that BA.2.86 may not pose the significant threat initially feared.
 Moreover, newly updated vaccines are expected to enhance antibody responses against all currently circulating variants, including BA.2.86. Clinical data shows a nearly nine-fold increase in neutralizing antibodies against this subvariant with Moderna's retooled vaccine. Similarly, Pfizer's updated shot demonstrates promising neutralizing activity.
In contrast, variant FL.1.5.1, known as "Fornax," is gaining traction and accounts for 14.5% of U.S. infections. This variant exhibits a higher level of immune evasion, causing concern among researchers. While the appearance of BA.2.86 initially raised worry, current findings suggest that it may not lead to a surge comparable to the previous Omicron wave. The unique characteristics of this variant have prompted extensive investigation, with global efforts underway to understand it better. 
In the United States, Europe, and Asia, there has been a rise in COVID infections and hospitalizations. However, these numbers are still lower than previous waves. According to CDC data for the week ending on August 26, the weekly growth rate of hospitalizations in the U.S. has slowed for three consecutive weeks.